June 2021 Humacyte Investor Update

June 11, 2021

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

June 10, 2021

Humacyte to Participate in Fireside Chat at Cowen 6th Annual FutureHealth Conference

June 08, 2021

Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment

June 04, 2021

Humacyte to Provide Investor Update on June 7

May 26, 2021

Humacyte Receives 2021 Life Sciences Award from Triangle Business Journal

May 22, 2021

Humacyte Announces Presentation by Principal Investigator Highlighting Clinical Experience with HAVs at Vascular Access Society of the Americas 2021 Spring Conference

May 21, 2021

Humacyte Presents Advances in Whole-Lung Engineering

May 19, 2021

Humacyte Appoints Dale Sander as Chief Financial Officer

May 06, 2021

Humacyte Leadership and Investigators to Present at Five Scientific Events in May

April 21, 2021

Humacyte Announces Positive Long-Term Follow-Up Data from Phase 2 Vascular Access Trial

April 14, 2021

Humacyte Secures $50 Million Debt Facility with Silicon Valley Bank

March 23, 2021

Humacyte CEO Dr. Laura Niklason and Alpha Healthcare CEO Rajiv Shukla to Present at CED Venture Connect 2021 Online Summit

March 11,2021

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

March 5, 2021

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021

February 17, 2021

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale, Going Public via Merger with Alpha Healthcare Acquisition Corp.

January 12, 2021

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

January 10, 2021

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11

December 9, 2020

Laura Niklason to Speak at Milken Institute Future of Health Summit

November 20, 2020

Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer

October 9, 2020

New Paper Defines Breakthroughs in Vascular Tissue Engineering

March 2, 2020

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

April 8, 2019

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

March 29, 2019

Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation"

January 8, 2019

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 1, 2020

Humacyte’s Bioengineered Blood Vessel Implanted by Clinicians at Walter Reed to Restore Blood Circulation to Retired Military Veteran’s Leg

November 19, 2020

Bioengineered human blood vessels

October 20, 2020

Humacyte and CNTR Team on MTEC Grant to Study the Evidence on Repair of Vascular Trauma

February, 2020

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

May 27, 2019

First Penn Scholarship Recipient off to Yale

May 23, 2019

Oh, the Places Grads Go

May 22, 2019

Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient

May 10, 2019

Bioengineered blood vessels could replace vasculature damaged by renal failure, CVD

April 9, 2019

Artificial blood vessels that come to life could improve medical care. Here’s why

April 4, 2019

TBJ reveals 2019 Life Sciences Awards winners

March 29, 2019

Study finds Humacyte acellular vessels repopulated to create living vessels

March 29, 2019

Scientists Make Blood Vessels From Cadaver Tissues And Bring Them to Life in Patients

Scroll to Top